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Since the initial discovery that a subset of patients with cutaneous melanoma harbor BRAF mutations, substantial research has
been focused on determining the pathologic consequences of BRAF mutations, optimizing diagnostic techniques to identify these
mutations, and developing therapeutic interventions to inhibit the function of this target in mutation-bearing tumors. Recently,
advances have been made which are revolutionizing the standard of care for patients with BRAF mutant melanoma. This paper
provides an overview on the pathogenic ramiﬁcations of mutant BRAF signaling, the latest molecular testing methods to detect
BRAF mutations, and the most recent clinical data of BRAF pathway inhibitors in patients with melanoma and BRAF mutations.
Finally, emerging mechanisms of resistance to BRAF inhibitors and ways of overcoming this resistance are discussed.
1.Introduction
Melanoma is currently the 5th and 7th most common cancer
in American men and women, respectively [1]. In addition,
the incidence of melanoma has risen dramatically over the
past 60 years, increasing faster than all other solid tumors
[2]. Although early-stage patients can be treated successfully
with surgical resection in the majority of patients, many
will develop disseminated disease. The prognosis for patients
with distant metastases from melanoma is dismal, and de-
spite standard treatment, greater than 95% of patients with
stage IV melanoma will die within ﬁve years and most pa-
tients succumb within one year.
More recently, preclinical discoveries have led to signif-
icant advances in the understanding of the key molecular
signaling events underlying the pathogenesis of melanoma.
Most notably, a high percentage of tumors of melanocytic
origin have been shown to harbor activating mutations of
BRAF, which lead to its constitutive activity. Approximately
70–80% of acquired melanocytic nevi and 40–60% of malig-
nant melanoma contain a BRAF mutation, the vast majority
of which result in a single amino acid change at codon 600
(BRAFV600E)[ 3, 4]. The resultant unopposed, constitutive
activationofextracellularsignal-regulatedkinase(ERK)leads
to the promotion of cellular growth and opposition of apop-
tosis and, ultimately, transformation into melanoma [5].
This enhanced signaling, however, also renders mutated cells
susceptible to the use of small molecule inhibitors which
target various BRAF pathway mediators [5–7].
2. RAFSignalingandPathogenesisofMelanoma
The interaction between a growth factor receptor and its
ligand typically induces a series of events, which promote
cellular growth and survival. The RAS family members are
GTPases which act as critical mediators in the transduction
of such signals. Though RAS plays an important role in the
homeostasis of normal cell turnover, death, and survival,
activating mutations in RAS family members (HRAS, KRAS,
and NRAS) have been identiﬁed and associated with various
human malignancies [8]. In melanoma, NRAS mutations
have been identiﬁed in 10–25% of tumor samples and
are thought to be an important driver of oncogenesis in
these patients [9–12]. Oncogenesis is mediated through the
upregulation of several downstream signaling mechanisms,2 Journal of Skin Cancer
most notably the mitogen-activated protein kinase (MAPK)
and the phophatidy-inositol-3-kinase (PI3K) pathways [13].
Activated RAS triggers MAPK pathway activation
through interactions with the RAF oncoproteins (BRAF and
CRAF) leading to the initiation of a progrowth signaling
cascade [14]. It is unclear whether it is BRAF or CRAF that
transmits signal from mutated NRAS to MEK, but the pre-
ponderance of evidence suggests that CRAF is the primary
mediator[15].RAFinteractswithMAPK/ERKkinase(MEK)
thereby initiating MEK phosphorylation which in turn leads
to an activating phosphorylation of ERK [14]. The activation
of ERK leads to a progrowth and transforming signal, which
appears to be critical to the pathogenesis of many malig-
nancies. This pathway can be initiated by either RAF iso-
form, BRAF, or CRAF, though CRAF also has pro-survival
eﬀects, in part through the upregulation of the anti-apop-
totic proteins, nuclear factor kappa B (NF-κB), and B-cell
leukemia 2 (BCL-2) [14]. Interestingly, unlike CRAF, acti-
vated BRAF has no other known substrates. Thus, BRAF
mutant melanomas signal exclusively through MEK and
subsequently ERK leading to oncogenesis. This characteristic
rendersthesetumorsexquisitelysensitivetopotentinhibitors
of the MAPK pathway.
3.Diagnostics/Detection
Since the identiﬁcation of activating mutations of BRAF
in melanoma, the technology for detection has improved
dramatically.StandardmutationaltestingforBRAFintumor
tissuetypicallyutilizestechniquessuchasbidirectionaldirect
ﬂuorescent sequencing and allele-speciﬁc polymerase chain
reaction which are commercially available and oﬀer high
speciﬁcity. The sensitivity of these assays, however, is limited
in that they are only able to detect the mutation if the
tumor cells constitute >5–10% of the specimen submitted
for genetic analysis [16, 17]. While this degree of sensitivity
is typically suﬃcient to detect the presence of the BRAFV600E
mutation in a homogenous tumor nodule, this is likely not
sensitive enough to detect a few tumor cells in the back-
ground of a high percentage of stromal or lymphatic ele-
ments, inﬁltrating lymphocytes, or peripheral blood cells.
One concern regarding the utilization of mutation detec-
tion techniques with enhanced sensitivity is that a positive
test might actually reﬂect the detection of a small subset
of mutant cells. While this might have interesting scientiﬁc
consequences, the clinical relevance of a tumor containing a
small amount of mutant BRAF cells is none, as these patients
would not be expected to beneﬁt from BRAF inhibitors.
This concern is warranted, as tumor heterogeneity has been
described in primary melanomas [18]. In addition, while
BRAF mutations are seen in the great majority of melano-
cytic nevi, vertical growth phase melanomas, and metastatic
melanoma, they are rarely detected in radial growth phase
melanomas (10%), which is thought to be the initial
malignant lesion prior to a frankly invasive lesion [19]. This
suggests that BRAF mutation may actually be an acquired
event in early melanoma that leads to clonal expansion and
tumor progression. Such polyclonality has not been seen in
individual metastatic tumors nor when tumors across mul-
tiplesitesfromindividualpatientsaresampled[18,20].Nev-
ertheless, the application of enhanced sensitivity mutational
analysis may not be just testing tumor samples but detecting
small numbers of representative tumor cells in a background
of nonmalignant cells such as in lymph nodes and peripheral
blood.
More advanced techniques and assays have been devel-
oped which either provide increased sensitivity or obviate
the need for increased sensitivity. These next generation tests
allow for more accurate testing on samples which contain
only a small amount of tumor, as well as for the detection
mutations in various peripheral blood components (i.e.,
lymphocytes, mononuclear cells, plasma, serum). The utility
of many of these tests have been explored in samples from
melanoma patients with varying results.
Ampliﬁcation refractory mutation systems (ARMSs) are
a recently described, allele-speciﬁc technique which has en-
hanced sensitivity (able to detect mutation sample contain-
ing 1% mutant cells) compared to standard DNA sequenc-
ing of formalin ﬁxed paraﬃn-embedded (FFPE) tissues
[21]. Another approach which greatly enhances sensitivity
for mutation detection is the utilization of assays which
selectively amplify mutant DNA/RNA in a sample. Using
a combination of allele-speciﬁc primers and locked nucleic
acid primers, the detection of 10 melanoma cells in 1mL of
blood has been described [22]. A third approach to increase
the sensitivity of mutation detection is reported to be able
to detect one mutant cell in a thousand nonmutant cells,
taking advantage of a unique restriction enzyme site in
the wild-type alleles which allows for the digestion of the
wild-type alleles and thus the enrichment of the mutant
alleles [23]. Finally, the incorporation of COLD-PCR leads
to a near doubling of sensitivity in the detection of BRAF
mutation from FFPE tissue when using standard sequencing
and pyrosequencing [24].
In addition to new technologies (ARMS) and modiﬁca-
tions to routine techniques which lead to a greater sensitivity
of mutation detection, the application of standard assays
on previously untested samples is also changing how we
approach BRAF testing. BRAF analysis on free DNA in the
serum and plasma has been reported as has the detection
of BRAF mutations from isolated, circulating tumor cells
(CTCs) [25–30]. While CTC, serum and plasma BRAF
analysis appears possible, it is yet to be determined whether
there will be routine clinical use for one or more of these
assaysorifthiswillremainasonlyanexperimentalapproach.
While the role of standard and experimental molecular
diagnostics is being utilized to identify speciﬁc mutations
of interest (i.e., BRAFV600E), both in tissue or blood, it also
maybeworthwhiletotestforothermutationsandanomalies
as these may indicate sensitivity to a particular treatment.
For example, Sequenom MassARRAY technology is being
used to query larger panels of oncogenic mutations, using
a primer extension reaction followed by mass spectrometry
to detect the products and identify mutations with potential
clinical consequences [31, 32]. Array comparative genome
hybridization (aCGH) oﬀers the opportunity to examine the
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ampliﬁcations and deletions that may confer sensitivity to
a targeted therapy [33]. However, all these technologies are
obviously limited in that they can only identify known,
preselected anomalies. Whole genome analysis (WGA) has
the potential to not only consolidate all or most of these
modalities and tests to a single technology platform but also
to identify additional genetic changes outside the design pa-
rameters of these other assays [34]. WGA also oﬀers the op-
portunity to uncover previously unknown (perhaps patient-
speciﬁc) mutations in melanoma genomes and to explore
whether particular proﬁles of mutations or polymorphisms
may be predictive of beneﬁt from a particular therapy (i.e.,
BRAF inhibitors, HD IL-2) [35]. Still, the clinical utility of
these “Next Generation” tests in the care of patients with
melanoma is completely unknown.
4. Inhibitorsof RAFSignaling(Lessto More
SpeciﬁcMutant BRAF, CRAF, MEK, Perhaps
Mention ERK Inhibitors)
A series of small molecule inhibitors have been developed
which target, with varying selectivity, wild-type BRAF,
BRAFV600E, other mutant BRAF (at the 600 and 601 posi-
tion), and CRAF. In addition, inhibitors of the downstream
mediators of RAF activation, namely MEK and ERK, are also
beingdeveloped.Inthissection,onlyagentswhichhavebeen
tested clinically and reported publically are reviewed.
5.BRAF Inhibitors
5.1. Sorafenib. Sorafenib, a multitargeted tyrosine kinase in-
hibitor of BRAF, CRAF, platelet-derived growth factor recep-
tor (PDGFR), vascular endothelial growth factor receptor
(VEGFR) 2, p38, and CKIT which was the ﬁrst RAF-inhib-
itor actively studied in patients with melanoma as it was
available for phase II testing in the same year in which BRAF
mutations were ﬁrst reported. Unfortunately, despite being
evaluated in numerous phase I, II, and III studies as a single
agent and in combination with chemotherapy, the clinical
utility of sorafenib has been disappointing. For example, in
a single agent trial of sorafenib, the median progression-free
survival for patients with melanoma was 11 weeks [36]. Six
patients (16%) had stable disease at 6 months that persisted
formorethan12monthsinsomecases.However,onlyoneof
the37patientsinthestudyhadanactualresponseevaluation
criteria in solid tumor (RECIST-) deﬁned tumor response.
This study was followed by several trials of sorafenib in
combination with various cytotoxic agents, though the com-
bination which was best studied was sorafenib, carboplatin,
and paclitaxel [37–42]. Initial promise with this regimen
was described in a phase I trial of sorafenib in combination
withcarboplatin andpaclitaxelinpatientswithsolidtumors,
where 24 patients with advanced melanoma were enrolled
[39]. Ten patients with melanoma (42%) achieved an
objective response, and an additional 11 patients (46%) had
stable disease based on RECIST. The median progression-
free survival was 43.7 weeks. These promising results led to a
phase III trial comparing carboplatin/paclitaxel ± sorafenib
in patients with melanoma that had progressed following
temozolomideorDTICtherapy.Thistrial(thePRISMstudy)
enrolled 270 patients and showed no beneﬁt for the addition
of sorafenib to carboplatin/paclitaxel in this second-line pa-
tient population [40]. The combination of carboplatin/pa-
clitaxel and sorafenib was also compared to carboplatin/pa-
clitaxel in a treatment na¨ ıve population of patients with
advanced melanoma in a placebo-controlled randomized
phase III trial performed within the United States Intergroup
(E2603).Thistrialenrolled800patientsandfoundnobeneﬁt
for the addition of sorafenib on either median PFS or OS
[41].
5.2.HigherPotencyBRAFInhibitors(PLX4032,GSK2118436).
One major explanation proposed for the ineﬀectiveness of
sorafenib as a single agent in patients with melanoma is its
inability to completely inhibit BRAF, and in particular, BRAF
containing the V600E mutation. Other inhibitors of BRAF,
such as PLX-4032 and GSK2118436, have been developed
andaremorepotent andselectiveinhibitors ofmutantBRAF
than sorafenib [6, 7]. This enhanced inhibition of BRAFV600E
predictably has led to improved clinical activity of these
agents compared to sorafenib.
5.3. Vemurafenib. Vemurafenib was the ﬁrst higher potency
BRAF inhibitor to complete phase I testing and show signif-
icant clinical beneﬁt [42]. In the phase I trial of PLX4032,
11 of the 16 patients with tumors bearing the BRAFV600E
mutation who received a dose ≥240mg twice daily in the
dose escalation phase experienced tumor responses while no
clinical responses were seen in the ﬁve patients with wild-
type BRAF-containing tumor. In addition, 26 of 32 (81%)
patients with the BRAFV600E mutant melanomas treated in
an expansion cohort at the recommended phase II dose of
960mg twice daily had a clinical response, including two
patients achieving a complete response (CR). The estimated
median PFS was seven months which compares favorably
to previously available therapies for metastatic melanoma.
Further, treatment with vemurafenib leads to a reduction in
levels of phosphorylated ERK (pERK) in tumors containing
the BRAFV600E mutation which is associated with clinical
response [43, 44]. Likely, this inhibition of pERK enhances
the splicing of the proapoptotic BCL-2 family member BIM
thereby promoting apoptosis of BRAFV600E cells [45].
These ﬁndings quickly led to the rapid accrual of both
a single-agent phase II study (BRIM2) and a randomized
controlledphaseIIItrial(BRIM3).ThephaseIItrialenrolled
132 patients with advanced melanoma who had received one
prior therapy. The objective response rate (ORR) was 53%
with a CR rate of 5%, and the progression-free survival was
6.7 months [46]. In the phase III trial, 675 patients with
advanced melanoma were randomized, to either the vemu-
rafenib or dacarbazine as front-line therapy [47]. At the ﬁrst
interim analysis, treatment with vemurafenib was associated
with a signiﬁcant reduction in the risk of death and the
risk of death (63% reduction) or disease progression (74%
r e d u c t i o n ) ,a sw e l la sam u c hh i g h e rO R R( 4 8 %v e r s u s5 % ) .
These ﬁndings served as the basis for the FDA approval of
vemurafenib in August 2011.4 Journal of Skin Cancer
5.4. GSK2118436. GSK2118436 is a second higher potency
BRAF inhibitor which has shown substantial clinical activity.
In a phase I/II trial, similar to PLX4032, patients with the
BRAFV600E mutation treated at the two highest dose levels
(150mg twice daily and 200mg twice daily) had a high re-
sponse rate (10/16 patients, 63%) [48]. In the eight pa-
tients with non-BRAFV600E mutations (V600K, V600G, and
K601E) treated at a dose of ≥100mg twice daily, three had
a partial response. Both of the patients with BRAFK601E
progressed after ﬁrst restaging, suggesting that only patients
with BRAF mutations at the 600 position will respond to
therapy.
6.MEKInhibitors
Inhibitors of MEK, the downstream mediator of RAF acti-
vation, and the only known substrate of BRAF have shown
promise in preclinical studies in melanoma and have begun
tobeinvestigatedintheclinicwithsomeencouragingresults.
MEK inhibitors may also be most useful in patients with
BRAFV600E mutation; as mutational status correlates strongly
with response to MEK inhibition in murine melanoma
xenograft models [49].
6.1. AZD6244. Two phase I trials of AZD6244 involving pa-
tients with advanced solid tumors showed this agent to be
well tolerated and to possess some antitumor activity in
patients with melanoma [50, 51]. In the ﬁrst trial, three
of eight with advanced melanoma patients treated with
AZD6244 achieved a partial response; BRAF and NRAS
mutational status was unavailable [50]. While in the second
phaseIstudy,onlyoneresponsewasseeninfourteenpatients
with melanoma, though this subject had a documented
BRAF mutation and a complete response ongoing for over
two years at the time of publication [51].
In addition, AZD6244 has shown promising results in
murine models, particularly in combination with chemo-
therapy, setting the stage for combination trials [52]. Build-
ing upon this, a pilot study of AZD6244 in combination
dacarbazine, docetaxel, or temsirolimus in patients with
advanced melanoma was performed [53]. Eighteen patients
were treated in whom BRAF and NRAS mutational status
was known. Clinical response was seen in ﬁve out of nine
patients (55%) with a BRAF mutation, whereas no responses
were seen in any of the nine patients without a BRAF muta-
tion which included four patients with an NRAS mutation.
In addition, time to progression was signiﬁcantly improved
inpatientswithaBRAFmutationcomparedtothosepatients
without (median 31 weeks versus 8 weeks).
6.2. GSK1120212. GSK1120212 is a reversible, selective in-
hibitor of MEK1/MEK2 which has been shown, in a phase I
trial, to have single-agent eﬃcacy in patients with advanced,
BRAFV600E mutant melanoma [54]. Speciﬁcally, eight of
20 patients with BRAF mutant melanoma treated with
GSK2110212 had a conﬁrmed response with two patients
achieving a CR. Interestingly, two of 22 patients with wild-
type BRAF had a PR with treatment, suggesting that some
melanoma tumors are dependent on ERK/MAP kinase sig-
naling despite the absence of a BRAF mutation.
6.3. PD-0325901. A phase I trial of PD-0325901 enrolled 48
patients with advanced melanoma, of whom 3 (6%) had a
conﬁrmed PR, 10 (21%) had stable disease for ≥4 months,
a n dat o t a lo f1 5( 3 1 % )p a t i e n t ss h o w e dr e d u c t i o ni nK i -
67 tumor staining [55]. Mutational analysis data of these
patients was not provided.
6.4. AS703026. Similar results have been recently reported
with AS703026, which is a potent MEK1/2 inhibitor. In the
phase I study, three of eight patients had a partial response
withtreatmentinoneoftwotreatmentschedules[56].Muta-
tional status of the melanoma patients was not reported.
WhiletheclinicaldataonMEKinhibitorsisencouraging,
it is quite preliminary. The true value of these agents
must await phase II and phase III trials in patients with
BRAF mutant melanoma. One such trial that is currently
ongoing is a randomized, phase III trial of GSK1220212
compared with chemotherapy (either dacarbazine or pacli-
taxel)inpatientswithmelanomaharboringBRAFmutations
(NCIT01245062).
7. EmergingMechanisms of Resistance to
BRAF Inhibition
Importantly, it appears that the great majority of patients
treated with single agent PLX-4032 will eventually exhibit
disease progression despite successful inhibition of the
BRAFV600E and a high rate of objective response early in the
course of therapy. Preliminary studies suggest that resistance
to PLX-4032 is not related to the development of a second
mutation which impairs the binding of the treatment drug to
BRAF, a resistance mechanism noted for targeted therapy in
othermalignanciessuchasnonsmallcelllungcancer,chronic
myelogenous leukemia, and gastrointestinal stromal tumor
[57–59].Instead,resistanceismediatedbyreactivationofthe
MAPK pathway in most tumors through alternative means.
It is from in vitro studies of BRAFV600E-mutated cells
which have been generated to exhibit acquired resistance to
BRAF inhibitors, that has led to the ﬁrst clues as to how
BRAF-mutated cells are able to survive BRAF inhibition.
It appears clear that reestablishment of MAPK signaling is
the key variable in acquired resistance to BRAF inhibition
[60–63]. This can be achieved through upregulation of
receptor tyrosine kinases (i.e., PDGFRB, ERBB2) [61, 62],
activation of RAS [60, 62], upregulation of CRAF [61, 63],
activation of the Ser/Thr MAPK kinases (COT) [61], and
development of a secondary activating mutation in MEK
[64, 65]. In addition, signaling through the PI3K pathway
initiated by insulin growth factor receptor 1 (IGF-1R) is
an alternative mechanism of acquired resistance which has
also been described [66]. Of note, each of these mechanisms
havebeen investigated andcorroboratedin smallnumbersof
tumor samples from patients who had biopsies performed at
the time of resistance, and dependence on those upregulated
or mutated signaling mediators was not demonstrated.Journal of Skin Cancer 5
Primary resistance to BRAF inhibition is seen in less
than 10% of patients with BRAF mutant melanoma treated
with vemurafenib [42]. While there is no data from clinical
samples which helps to identify which patients are likely
not to beneﬁt from BRAF inhibitors, preclinical studies sug-
gest that elevated pretreatment levels of CRAF, as well as,
baseline CCND1 ampliﬁcation in tumors, leading to down-
stream overexpression of Cyclin D1 and enhanced CDK4
expression, are promising pretreatment biomarkers worth
further investigation [63, 67].
InBRAFwild-type(BRAFWT)melanomacells,theMAPK
kinase pathway is activated by vemurafenib (and the anal-
ogous PLX4720) leading to upregulation of MEK and ERK
and enhanced proliferation [68, 69]. This appears to be
secondary to the activation of CRAF with subsequent down-
streamsignalingthroughMEKandERKwithexpectedonco-
genicconsequencesinBRAFWT cells[69].Further,thisCRAF
activation appears to be mediated through the formation
of a heterodimer with the BRAFWT protein and/or CRAF
homodimer which is most apparent in RAS-mutated cells
[70, 71]. In addition, PLX4720 enhances the levels of the
antiapoptotic BCL-2 family member protein MCL-1 in
NRAS mutant melanoma cells through enhanced signaling
through the MAPK pathway [72]. While it is clear that
CRAF activation and enhanced MAPK pathway signaling
occur in BRAFWT melanoma cells (particularly those which
harbor an NRAS mutation) treated with BRAF inhibitors
such as vemurafenib and PLX4720, the clinical relevance of
this is uncertain. Speciﬁcally, it is not thought that clinically
acquired resistance to vemurafenib, for example, occurs
solely due to growth of a subset of BRAFWT melanoma cells
as persistence of the BRAFV600E mutation has been identiﬁed
inalltumorsanalyzedandreportedtodate.Infact,itappears
t h a ts p e c i ﬁ cc h a n g e si nB R A F V600E-mutated cells allow for
adaptations which lead to renewed growth despite continued
BRAF inhibition.
8. FutureDirections
The establishment of single-agent eﬃcacy of selective BRAF
inhibitors, and to lesser extent MEK inhibitors, is a major
breakthrough for the treatment of patients with BRAF muta-
tion positive melanoma. Though most patients treated with
these agents are predicted to progress on treatment, the
elucidation of the mechanisms of resistance described above
helps guide future sequential and combinational therapy.
Based on the ﬁnding that MAPK pathway activity is reac-
tivated in melanoma following selective BRAF inhibition,
the ﬁrst combination trial of a selective BRAF inhibitor
(GSK2118436) with a MEK inhibitor (GSK1120212) is
underway and appears tolerable with both agents being ad-
ministered at their standard single-agent doses [73]. In ad-
dition to this combination, trials with selective BRAF in-
hibitors either in combination with or followed by IGF-
R1 antagonists and other receptor tyrosine kinase inhibitors
might be anticipated from the results of preclinical models of
resistance [61, 62, 66].
Another approach to enhancing the eﬀectiveness of se-
lective BRAF inhibitors and MEK inhibitors is the addition
of agents which might augment apoptosis. One such agent
is ABT-263 which is a BH3-mimetic currently in clinical
development. In preclinical studies, the less bioavailable
homologous BH3-mimetic ABT-737 in combination with
a MEK inhibitor led to enhanced lethality compared to
either agent alone [74]. Whether ABT-263 in combination
with MEK or selective BRAF inhibitors will improve clinical
outcomes is unknown, though it is perhaps worth exploring
in an early-phase clinical trial.
In addition to combination therapy with molecularly
targeted agents which inhibit signaling induced by selective
BRAF inhibition or promote apoptosis, another promising
approach to maximizing the beneﬁt of BRAF or MEK in-
hibiters is to combine these agents with immunotherapy.
Recently, immune checkpoint inhibitors, including the anti-
CTLA-4 monoclonal antibody ipilimumab and the anti-
PD monoclonal antibody MDX-1106, have shown single
agent eﬃcacy in patients with metastatic melanoma [75, 76].
Importantly, it appears that PLX4032 does not adversely
aﬀect human T-lymphocytes (T-cells) function while MEK
inhibitors do [77]. Further, vemurafenib has been shown to
improve immune recognition by antigen-speciﬁc T cells in
melanoma [78]. These ﬁndings provide a rationale for a
study evaluating the safety and eﬃcacy of selective BRAF
inhibition in combination with immunotherapy, including
ipilimumab, MDX1106, and possibly high-dose IL2.
9. Conclusions
It had been hoped for many years that the growing under-
standing of the molecular pathways involved in melanoma
development and the increasing availability of speciﬁc
inhibitors of these pathways would enable the rational de-
velopment of future therapies. With the emergence of ve-
murafenib and GSK2118436, the ﬁrst molecularly targeted
agents to lead to tumor responses in a large percentage of
patients, a new approach to the treatment of melanoma has
begun. As a result, all patients with advanced melanoma
should have BRAF mutational analysis prior to commencing
systemic therapy. In those patients whose tumors harbor a
mutation in BRAF, every attempt should be made to treat
these patients with either of the two highly potent BRAF
inhibitors. Additionally, as more is learned about the resis-
tance mechanisms to BRAF inhibitors, the development of
combination trials of novel molecularly targeted therapies
can be expected; further clinical improvements can only be
sorted out by carefully conducted preclinical and clinical
studies that include pretreatment and on-treatment biopsies.
With BRAF being established as the ﬁrst point of vulnerabil-
ity in melanoma, it is hoped that a molecular understanding
of the limits of BRAF inhibition will lead to further clinical
beneﬁt.
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